Expression of miR-210 in relation to other measures of hypoxia and prediction of benefit from hypoxia modification in patients with bladder cancer

BACKGROUND: The addition of hypoxia modifiers carbogen and nicotinamide (CON) to radiotherapy (RT) improved overall survival (OS) in bladder cancer patients in the BCON phase III clinical trial. We investigate whether expression of hsa-miR-210 in BCON patient samples reflects hypoxia and predicts be...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Cancer
Hlavní autoři: Irlam-Jones, J J, Eustace, A, Denley, H, Choudhury, A, Harris, A L, Hoskin, P J, West, C M L
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2016
Témata:
Molecular Diagnostics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4997544/
https://ncbi.nlm.nih.gov/pubmed/27441495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.218
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky